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Abstract
Background: Debilitating brain injury occurs in 1.6–5 % of patients undergoing cardiac surgery with cardiopulmonary
bypass. Diffusion-weighted magnetic resonance imaging studies have reported stroke-like lesions in up to 51 % of
patients after cardiac surgery. The majority of the lesions seem to be caused by emboli, but inadequate blood flow
caused by other mechanisms may increase ischaemia in the penumbra or cause watershed infarcts. During
cardiopulmonary bypass, blood pressure can be below the lower limit of cerebral autoregulation. Although much
debated, the constant blood flow provided by the cardiopulmonary bypass system is still considered by many as
appropriate to avoid cerebral ischaemia despite the low blood pressure.
Methods/design: The Perfusion Pressure Cerebral Infarct trial is a single-centre superiority trial with a blinded
outcome assessment. The trial is randomising 210 patients with coronary vessel and/or valve disease and who are
undergoing cardiac surgery with the use of cardiopulmonary bypass. Patients are stratified by age and surgical
procedure and are randomised 1:1 to either an increased mean arterial pressure (70–80 mmHg) or ‘usual practice’
(40–50 mmHg) during cardiopulmonary bypass.
The cardiopulmonary bypass pump flow is fixed and set at 2.4 L/minute/m2 body surface area plus 10–20 % in
both groups.
The primary outcome measure is the volume of the new ischaemic cerebral lesions (in mL), expressed as the difference
between a baseline, diffusion-weighted, magnetic resonance imaging scan and an equal scan conducted 3–6 days
postoperatively. Secondary endpoints are the total number of new ischaemic cerebral lesions, postoperative cognitive
dysfunction at discharge and 3 months postoperatively, diffuse cerebral injury evaluated by magnetic resonance
spectroscopy and selected biochemical markers of cerebral injury.
The sample size will enable us to detect a 50 % reduction in the primary outcome measure in the intervention
compared to the control group at a significance level of 0.05 and with a power of 0.80.
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Discussion: This is the first clinical randomised study to evaluate whether the mean arterial pressure level during
cardiopulmonary bypass influences the development of brain injuries that are detected by diffusion-weighted
magnetic resonance imaging.
Trial registration: ClinicalTrials.gov, NCT02185885. Registered on 7 July 2014.
Keywords: Cardiopulmonary bypass surgery, Cardiac anaesthesia, Ischaemic stroke, Embolic stroke, Postoperative
cognitive dysfunction
Background
Cerebral injury is a serious complication after cardiac
surgery with the use of cardiopulmonary bypass (CPB)
[1, 2]. Several preoperative risk factors have been iden-
tified, most importantly age, proximal aortic athero-
sclerosis and a history of neurologic disease [1, 3]. The
pathophysiology behind cerebral dysfunction after CPB
ranges from reversible cell dysfunction to cell death,
causing infarcts.
Cerebral infarcts may be caused by emboli, thrombi
and/or regional hypoperfusion, with emboli being consid-
ered the most common cause. Embolic material can arise
from fragments of atherosclerotic plaques, fat, air bubbles
and particles from technical equipment [4]. After on-
pump coronary artery bypass grafting (CABG) 1.6–5 % of
patients experience a stroke, and this risk increases with
age [1–3]. When using diffusion-weighted magnetic res-
onance imaging (DWI), the reported incidence of new is-
chaemic infarcts in relation to CABG is from 26 to 51 %
[5, 6]. Corresponding incidences also have been reported
for heart valve surgery [7, 8] (Fig. 1).
Apart from the aetiologies mentioned above, the perfu-
sion pressure during CPB, i.e. the mean arterial pressure
(MAP), may contribute to the occurrence of PPCI. The
concept of cerebral autoregulation, has been shown to
apply not only under regular physiologic conditions be-
tween MAP levels of 50–150 mmHg [9, 10] but also dur-
ing heart surgery with non-pulsatile CPB and moderate
haemodilution, where the autoregulation of the cerebral
blood flow (CBF) in securing a flow-metabolism coupling
[11–14] is limited to a functional range of cerebral perfu-
sion pressure (CPP) between 40 and 120 mmHg [15].
Based on the results from humane clinical studies, Govier
et al. [16] and Murkin et al. [14, 17] reported that CBF
was independent of MAP down to 30 mmHg or CPP (ap-
proximately the MAP minus the jugular venous pressure)
of 20 mmHg during hypothermic CPB.
Though debated for many years, the topic of perfusion
pressure strategy is still controversial, as many questions
remain unanswered. Below the lower limit of autoregula-
tion (LLA), CBF varies directly with CPP, and conse-
quently, the CBF may be pressure-limited, potentially
resulting in ischaemic injury. Thus, some have argued a
MAP of approximately 50 mmHg during CPB suffices to
secure adequate tissue perfusion [18, 19], whereas others
have criticized this simplistic application of a classic cere-
bral autoregulation theory [20, 21] and advocated higher
mean pressures (70–80 mmHg) [22] because a right shift
of the LLA is expected in atherosclerotic and chronically
hypertensive patients [23].
Fig. 1 Diffusion-weighted magnetic resonance imaging (DWI) scans of a Perfusion Pressure Cerebral Infarct (PPCI) pilot study participant before
(a) and after (b) heart surgery with the use of cardiopulmonary bypass (CPB). The images reveal two silent cerebral infarcts marked by white arrows
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To increase the MAP, a supply of vasoconstrictors is
often needed. In a study of 12 anaesthetised swine,
O’Dwyer et al. [13] found that an increase of MAP with
phenylephrine caused significantly lower values of splanchnic
blood flow compared to an increase of MAP achieved
by an elevation of pump flow. In general, norepineph-
rine (α (β)-receptor agonist) and phenylephrine (α1-re-
ceptor agonist) are considered to have minimal effects
on the cerebral circulation and metabolism in healthy
subjects, but several studies indicate a change of condi-
tions when the integrity of the blood-brain barrier is
compromised [24–26]. In that situation and in the clin-
ical event of an intraoperative stroke or a pronounced
inflammatory reaction, norepinephrine is speculated to
interact with the α-adrenergic receptors of cerebral ves-
sels, thereby causing vasoconstriction and increased
oxygen consumption, which may enhance ischaemia in
the penumbra of an embolic stroke or an area of re-
gional hypoperfusion. Physiologically, surgical stress
and critical illness are potent endogenous stimuli of the
sympathetic nervous system, and when exogenous ad-
renergic drugs are added, the risk of adverse effects,
such as hypercoagulability, tachyarrhythmias, diastolic
dysfunction etc., increase as a consequence of sympa-
thetic overstimulation [27].
Until now, only three randomized clinical trials have in-
vestigated the importance of MAP during CPB on neuro-
logical and cognitive outcomes [22, 28, 29]. In all three
trials, a target MAP of 80 mmHg or above in the high
pressure group was compared to various levels of control
group MAPs. Gold et al. found a significant difference in
favour of high pressure with the primary endpoint of
major cardiac and neurological morbidity but found no
significant difference in the isolated neurological compli-
cations. A decade later, Charlson et al. found no difference
when comparing a target MAP of 80 mmHg to a custom
pre-bypass pressure MAP. In a more recent study, the in-
cidence of neurocognitive dysfunction and delirium was
lower in patients with high MAP. These somewhat con-
flicting observations could be related to the patient selec-
tion, methodology or choice of endpoint. For this reason,
neuroimaging with identification of newly developed in-
juries may provide a more reliable estimate of neurological
injuries at different MAP management levels, and the
present study will be the first to do so in a clinically ran-
domised fashion.
In conclusion, the importance of MAP during CPB on
cerebral complications after cardiac surgery is unknown
[30]. The task of avoiding a hypotension-induced limita-
tion of flow may come at the price of increasing the risk
of cerebral vasoconstriction and hypercoagulability due
to the necessary application of vasopressor therapy.
Thus, this state of equipoise inarguably justifies the sci-
entific efforts made towards a clarification of benefit
versus risk in the application of the different MAP strat-
egies during CPB.
Aim
The aim of the PPCI trial is to assess the effects of
two distinctive levels of MAP during CPB on the de-
velopment of perioperative cerebral injury in cardiac
surgery patients.
Methods/design
This trial is a single-centre superiority trial with a
computer-generated allocation sequence, centralised
web-based randomisation and blinded outcome assess-
ment of patients with coronary vessel and/or valve dis-
ease undergoing cardiac surgery with the use of CPB in
a university hospital in the capital region of Denmark.
Patients will be stratified by age (stratum 1: 18–70 years;
stratum 2 ≥ 70 years) and by the type of cardiac surgery
(stratum 1 - surgery involving the aortic and/or mitral
valve; stratum 2 - surgery not involving these valves), and
randomised 1:1 to either an increased MAP (70–80 mmHg)
or ‘usual practice’ in our institution (typically 40–50 mmHg)
during CPB. In both groups, the CPB blood flow is main-
tained while fixed at 2.4 L/minute/m2 body surface area
plus 10–20 %, unless the surgical procedure conditions re-
quire a transient reduction in flow.
Based on the results of a pilot study including 12 pa-
tients, a sample size calculation for the main trial was
performed. The trial flow chart is shown in Fig. 2. For a
populated SPIRIT checklist, please see Additional file 1.
Hypothesis
If, and to what extent, MAP should be increased dur-
ing CPB to reduce cerebral complications after cardiac
surgery remains controversial because the present evi-
dence is not sufficient to support one perfusion pres-
sure strategy over another, which underscores the
need for this trial.
Our hypothesis is that a MAP of 70–80 mmHg with a
fixed blood flow during CPB reduces the extent of DWI-
evaluated brain injury after cardiac surgery compared to
a MAP of 40–50 mmHg during CPB.
Trial intervention
The trial includes two different groups.
 Intervention group: The CPB procedure is conducted
according to department guidelines with the
modification that MAP is maintained between 70
and 80 mmHg.
 Control group: The CPB procedure is conducted in
accordance with department guidelines, where MAP
is sought to be ≥ 40 mmHg (typically 40–50 mmHg).
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Fig. 2 The Perfusion Pressure Cerebral Infarct (PPCI) trial flow chart
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CPB blood flow is intended to be equal and fixed in
the two groups. The requested MAP level is achieved by
intermittent intravenous doses of phenylephrine to a
total maximum of 2.0 mg and takes place after that con-
tinuous intravenous infusion of norepinephrine up to
0.4 μg/kg/min.
Inclusion criteria
Patients included in the trial are as follows:
 ≥18 years of age
 Scheduled for elective or subacute cardiac surgery
with the use of CPB
 Scheduled for CABG and/or heart valve surgery
 Contraindications to magnetic resonance imaging
(MRI)
Exclusion criteria
Patients fulfilling one or more of the following criteria
will not be included:
 A history of stroke or intracranial bleeding
 A history of reversible ischaemic deficits (duration
of symptoms 24–72 hours)
 A history of transient ischaemic attacks (duration of
symptoms < 24 hours)
 Diagnosis of neurodegenerative disorders such as
Alzheimer’s, multiple sclerosis etc.
Randomisation
Trial coordinators (Anne G. Vedel and Frederik Holmgaard)
have 24-hour access to a web-based screening and
randomisation system externally developed and supplied by
Zenodotus ApS (directed and managed by Dan Høfsten,
MD, PhD - CVR-no.: 33 52 41 02 (Danish Central Com-
pany Registration no.), Hundested, Denmark) and will, after
the entry of stratification variables (age less than 70 years or
more than/equal to 70 years; surgery involving the aortic
and/or mitral valve or surgery not involving these valves)
enrol participants and assign them to either the control or
intervention group treatment (Fig. 2a and b). The allocation
list is computer generated by Zenodotus ApS, with varying
block sizes of four to eight, and allocation will, at all times
during the PPCI data collection, be concealed to both the
trial coordinators and other project group members.
All patients scheduled for elective or subacute CABG
and/or heart valve surgery in our institution for the dur-
ation of the recruitment period will be screened for
eligibility.
Primary outcome measure
 The total volume of new ischaemic cerebral lesions
(sum in mL), which is expressed as the difference
between a DWI scan conducted preoperatively and
one conducted on the third to sixth postoperative day.
Secondary outcome measures
 The total number of new ischaemic cerebral lesions—
expressed as the difference between a DWI scan
conducted preoperatively and one conducted on the
third to sixth postoperative days
 Magnetic resonance spectroscopy (MRS) [31] —
change from baseline N-acetylaspartate-creatine
(NAA/Cr) ratio at days 3–6
 MRS —change from baseline total choline/creatine
(Cho/Cr) ratio at days 3–6
 Biochemical markers of brain injury—change from
baseline blood concentration of S100ß, neuron-
specific enolase (NSE), phosphorylated neurofilament
heavy protein (pNfH), glial fibrillary acidic protein
(GFAP), matrix metallopeptidase 9 (MMP-9) and ubi-
quitin c-terminal hydrolase 1 (UCH-L1) [32, 33]at
three time points: 24 and 48 hours after surgery com-
mencement and on discharge from the surgical ward
 Postoperative cognitive dysfunction (POCD) [34]
—change from baseline neuropsychological test
performance at days 3–8 (i.e. performance at
discharge from surgical ward)
 POCD —change from baseline neuropsychological
test performance at 3 months
 Near Infrared Spectroscopy (NIRS)—change from
pre-anaesthesia regional cerebral oxygen saturation
(rcSO2), measured bilaterally
 Neurologic status — new neurological deficits at
discharge from surgical ward.
 Microcirculatory evaluation — intraoperative change
in sublingual capillary perfusion evaluated using
Sidestream Dark Field (SDF) imaging technique [35]
at three intraoperative time points: (1) after
anaesthesia induction, before surgery
commencement; (2) during CPB; and (3) after CPB
during skin closure
 GAMPT bubble detection — count and volume of
bubbles (5–500 μm) in the arterial line of the CPB
circuit for the duration of the bypass procedure
Anaesthesia and CPB procedure
During the CPB procedure, we will use a fixed-flow ap-
proach (where the pump flow is set at 2.4 L/minute/m2
body surface area plus 10–20 %) and the vasoactive ther-
apy regimen described in the trial intervention section.
All concomitant medication or treatment interventions
will be at the treating clinicians’ discretion.
Our department guidelines on anaesthetic and CPB pro-
cedure approaches are as follows in this paragraph: anaes-
thesia is induced with fentanyl (10 μg/kg), propofol (1 to
Vedel et al. Trials  (2016) 17:247 Page 5 of 11
2 mg/kg) and cisatracurium (0.1 mg/kg) and maintained
with sevoflurane (0.5 % to 3 %) and a continuous infusion
of remifentanil (15 to 30 μg/kg/hour). Two peripheral
veins, one radial artery and an internal jugular vein are
cannulated. Transoesophageal echocardiography and a pul-
monary artery catheter are used when considered neces-
sary by the anaesthetist and/or surgeon. The ventilation
mode is volume controlled, without the use of positive
end-expiratory pressure (PEEP) intraoperatively, and lung
recruitment is performed after CPB. After heparinization
(350 IU/kg, ACT > 480), an angled arterial cannula
(DLP 24 FR, Medtronic Inc., Minneapolis, MN, USA) is
surgically placed in the ascending aorta followed by a
two-stage venous cannula (36/46 FR, Medtronic) in the
right atrial appendage. Normothermic CPB perfusion with
non-pulsatile flow is performed using membrane oxygen-
ation with an integrated arterial filter of 25 μm (Affinity
Fusion, Medtronic Inc., Minneapolis, USA) and a roller
pump (Stockert S5, Sorin Group, Milano, Italy).
For routine procedures, we do not use rcSO2 monitoring
or arterial line bubble detection [36, 37] in our institution.
Accordingly, in this trial, data will be collected only as part
of the research protocol. Intraoperatively, we will continu-
ously collect cerebral NIRS data (using Somanetics INVOS
5100C oximeter (Medtronic/Covidien, Denmark)) [38, 39]
and save it for later analysis. We will conceal and mute
the NIRS monitor during the procedure. Integrating the
GAMPT BCC200 (GAMPT GmbH, Merseburg, Germany)
into the CPB-machine enables us, through ultrasound Dop-
pler techniques, to detect gaseous microemboli (GME, vol-
ume between 5 and 500 μl). In our setup, an ‘arterial’ probe
is placed after the oxygenator on a 3/8 inch non-coated
PVC tubing line and a ‘venous’ probe is place on a 3/8 inch
non-coated PVC tubing line between the roller pump and
the oxygenator in the CPB circuit.
Magnetic resonance imaging protocol
DWI visualises changes in the self-diffusion of water
molecules. The technique is highly sensitive for de-
tecting brain ischemia because it enables a distinction
between infarction-associated cytotoxic oedema and
vasogenic oedema [40, 41].
We will obtain baseline MRI the day before the sched-
uled surgery and once again between the third and sixth
postoperative day using the same 3 Tesla scanner (Mag-
netom Verio, Siemens, Erlangen, Germany – software
NUMARIS/4, version syngo MR B17). Our imaging
protocol will include a sagittal T1, an axial T2, a coronal
fluid-attenuated inverse recovery (FLAIR) and an axial
DWI sequence. The latter sequence will have a slice
thickness of 4 mm and a distant factor of 1.2 mm.
When possible (taking factors related to somatic con-
dition, patient compliance and MRI logistics into ac-
count), we will expand the imaging protocol and also
obtain short-echo-time proton magnetic resonance spec-
tra [31] from two volumes of interest (VOIs) located in
parieto-occipital white matter (volume 25 × 25 × 20 mm
[3]) and occipital grey matter (volume 21 × 27 × 20 mm
[3]), respectively (PRESS, TE 30 ms, TR 3000 ms, 80 ac-
quisitions [42]). This will enable us to evaluate cerebral
metabolism, including changes from baseline at the third
to sixth postoperative days using the metabolite ratios
for N-acetylaspartate/total creatine (NAA/Cr) and total
choline/total creatine (Cho/Cr).
Blood samples
We will collect blood samples at four different time points
during the admission: (1) intraoperatively before CPB; (2)
24 hours post-anaesthesia induction; (3) 48 hours post-
anaesthesia induction and (4) on discharge from the surgi-
cal department. All samples collected will be venous and
drawn from either a central venous line or a cubical vein,
except for sample number 1, which will be drawn from
the catheter in the radial artery. At each time point, a total
of 9 mL is drawn and divided between ethylenediamine-
tetraacetate (EDTA), citrate-coated and heparin-coated
tubes. We will centrifuge the samples for 10 min at
3000 rpm while cooling to 4 °C and then extract and store
the plasma in polypropylene test tubes at −80 °C until en
bloc assaying can be performed.
Postoperative cognitive dysfunction
The trial coordinators (Anne Grønborg Vedel and Fre-
derik Holmgaard) will evaluate the patients’ cognitive
function on three occasions: (1) the day before surgery;
(2) the day before discharge from the surgical ward and
(3) after 2–4 months. Each time, they will use the
ISPOCD test battery [34], which consists of a ‘Visual
Verbal Learning test’, a ‘Concept Shifting test’, a ‘Stroop
Colour Word Interference test’ and a ‘Letter Digit Cod-
ing test’.
As the ISPOCD test battery is developed for patients
with an intact cognitive capability, we will conduct a
Mini-Mental State Examination (MMSE) to screen for
cognitive impairment, i.e. signs of dementia. If a patient
has a baseline MMSE score of 24 or less, that patient will
not undergo further cognitive testing during the trial.
Blinding
Patients will be blinded from the group allocation. Add-
itionally, healthcare providers in the intensive care unit
and ward will be unaware of the assigned MAP strategy,
unless they specifically consult the handwritten anaesthesia
report and, based on the continuous registration of MAP
data, guess to which group the patient has been allocated.
Throughout the trial, we will stress that the staff involved
in the experimental setup in the operating room may at no
point disclose group allocation.
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Since the trial coordinators will conduct screening, pa-
tient inclusion/randomization and intervention communi-
cation along with MRI scans, POCD tests, blood sample
handling and neurological examinations, they cannot be
blinded to the assigned MAP strategy. However, assessors
of the primary and selected secondary endpoints (DWI
scans, MRS and POCD) will be blinded to treatment allo-
cation. Furthermore, blood samples will be labelled with a
unique patient number, and personnel carrying out blood
sample analysis will not know the group allocation.
The independent trial statistician will also be blinded
to the allocation during analysis of both the primary and
secondary endpoints.
Participant withdrawal
Patients may withdraw their informed consent to partici-
pate in the trial at any time. If consent is withdrawn on
the day of surgery before anaesthesia induction, the trial
intervention will be cancelled along with further data
registration. Should a patient wish to withdraw their con-
sent to participate in the trial after the surgical procedure
has been performed, we will ask the patient to consider
participating in some but not all of the trial investigations,
in order to collect as much post-intervention data as pos-
sible. However, if the patient declines and requests a full
withdrawal, no data will be collected. We will report data
on all randomized patients and also, to obtain the full
sample size, include and randomize additional patients to
compensate for missing data regarding the primary out-
come measure.
To promote the retention of trial participants, we will –
when logistically doable – conduct the 3-month neuro-
psychological test in the participants’ private homes,
should they decline to participate in a follow-up visit at
the hospital investigation site due to transportation issues.
Safety and monitoring
The trial protocol may be suspended for the individual
patient at the discretion of the anaesthetist in case of un-
foreseen haemodynamic challenges that require a differ-
ent CPB strategy to keep the patient safe.
Missing data on the primary outcome are to be ex-
pected, We will obtain an MRI between the third and
sixth postoperative day and do expect some missing data
on the primary endpoint, since patients must be fully
awake and able to complete a 10-min MRI stroke scan-
ning protocol in the supine position with a nasal cannula
delivering no more than 3 litres oxygen/min.
There will be no protocolised interim analysis during
the trial. We will record severe adverse events (SAE), de-
fined as stroke, acute myocardial infarction, acute kidney
injury, gastrointestinal complications (defined as condi-
tions leading to acute explorative laparoscopy/laparotomy)
and postoperative bleeding resulting in reoperation,
and in addition, mean lactate levels. The trial steering
and management committee will monitor and compare
the SAE and mean lactate levels between the two
groups after inclusion of 50 and 120 patients. Should
there be significant differences in frequency of SAE or
lactate levels, we will facilitate a critical review of data
performed by an external monitoring group, before we
continue data collection.
Statistics
Using the results from the pilot study, the sample size in
the present trial has been determined in order to allow
for the detection of a 50 % reduction in the primary out-
come measure in the intervention as compared to the
control group (from 0.18 to 0.09 mL, SD 0.20 mL) at a
significance level of 0.05 and with a power of 0.80. The
power calculation was based on a t test and showed that
2 × 78 participants would be needed. To compensate for
possible non-normal distribution of data, attrition and
other causes of missing data, the total number of partici-
pants is planned to be 2 × 105.
The primary outcome will be compared between the
intervention and the control group and adjusted for strati-
fication [43, 44]. It will be expressed as mean difference
with 95 % confidence interval. The analyses will be carried
out using multiple linear regression analysis entering
randomization and stratification status (age less than
70 years or more than/equal to 70 years; surgery involving
the aortic and/or mitral valve; or surgery not involving
these valves), as well as preoperative total volume of is-
chaemic cerebral lesions as independent variables. The
primary analysis will be performed according to the
intention-to-treat principle [45]. In addition, an un-
adjusted intention-to-treat analysis and a stratification-
adjusted per-protocol analysis excluding patients with
major protocol violations will be done.
The neurocognitive tests examine the changes in per-
formance for each of the four test variables used, com-
paring the baseline/first test session with the second and
third sessions. A subtraction of the average learning ef-
fect is performed as described by the ISPOCD-group
[34]. Patients have cognitive dysfunction when two out
of seven Z-scores for individual test variables or the
composite Z score is > 1.96.
Intergroup differences in the additional secondary out-
come measures will be compared using chi-squared tests
with OR and 95 % confidence interval or two-group t
tests/Mann Whitney tests, depending on the type of data
and their distribution. Intragroup differences (course over
time) of blood levels of biochemical markers of brain in-
jury will be examined using repeated measures analysis of
variance (ANOVA). Finally, a number of exploratory ana-
lyses will be carried out using multiple regression analysis.
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If more than 5 % of the cases (10 patients or more)
have missing data for any particular analyses and the
data can be justified as missing at random, the analyses
will be conducted using multiple imputations. The mul-
tiple imputation procedure will be based on all available
data for that patient and be conducted using the chained
equation approach. If data are not missing at random,
the analyses will be carried out using available data with
appropriate interpretational reservations.
Differences in the primary outcome measure will be
considered statistically significant if the P value is less
than 0.05. Analyses of the secondary outcome measures
are considered significant if the P values are less than
0.01. Only two-sided tests will be used. Statistical ana-
lysis will be performed using R statistical software and
the Statistical Analysis System software (SAS Institute
Inc., Cary, NC, USA).
Data registration
Data will be registered in the case report form (CRF)
from patient notes (source data) by the trial coordina-
tors. The primary trial coordinator, in cooperation with
the primary trial investigator, will establish the trial data-
base by entry of data from the paper CRFs. A data valid-
ation will be performed on 10 % of entered data.
The following data will be registered:
Pre-randomization and baseline characteristics:
 National identification number, sex, ethnicity, age
at randomization, height in cm, weight in kg, co-
morbidities (previous cardiac, lung, neck or brain
surgery, previous thoracic irradiation, previous ad-
mission for heart failure, stable or unstable angina,
myocardial infarction, cardiac arrhythmia, asthma,
COPD, chronic treatments for arterial hypertension,
hypercholesterolemia, diabetes, cancer, habitual p-
creatinine, estimated glomerular filtration rate (eGFR))
 A detailed heart and lung status, including data
from coronary angiography, echocardiography and
pulmonary function tests
 Results from pre-operative blood samples (standard
laboratory values), alcohol, tobacco and medication
status
Intra-operative data:
 Cardiac rhythm, heart rate, MAP, central venous
pressure, pulmonary arterial pressure, mixed venous
oxygen saturation, cardiac output and fraction of
inspired oxygen
 Operating, perfusion and aortic cross clamp time, use
of aortic side clamp, number of grafts anastomosed to
the aorta, plaques in the aorta when described by the
surgeon, total volume of phenylephrine and
norepinephrine administered, end surgical fluid status,
total volume of various inotropic agent administered,
use of blow-by CO2 in the surgical site, NIRS data
and GAMPT BCC200 data
Postoperative data:
 Cardiac status (arrhythmias, pacemaker need >
24 hours after surgery, direct current conversion,
postoperative myocardial infarction (according to
ESC classification (ref.)), treated pericardial
effusion, maximal level of creatine kinase isoenzyme
MB (CK-MB) and troponin T (TnT), coronary
angiography), neurological status (stroke, symptoms
of delirium (that results in acute administration of
antipsychotic medication), convulsions), respiratory
status (total intubation time, reintubation, pneumonia,
treated pleural effusion, need of supplementary
oxygen > 2 days), haemorrhage (amount in mL
24 hours post operation, need of transfusions (total
volume and type)), gastrointestinal status (ulcer,
severe obstipation, ileus, intestinal ischemia), renal
status (maximal creatinine during hospital stay, renal
replacement therapy)
 Intensive care unit length of stay (ICU-LOS) in
hours, readmission to intensive care unit ICU, need
and reason for reoperation, total hospitalization time
including stay in the department of cardiac surgery,
blood samples (standard laboratory values),
destination at discharge (home, local hospital or
organ specific department)
2–6 months after randomization:
 Cardiac status (New York Heart Association
(NYHA) and Canadian Cardiovascular Society
(CCS) classification, arrhythmias, persistent
pacemaker need, myocardial infarction, heart
failure, peripheral ischemia, venous thrombosis),
respiratory status (admission to hospital due to
pleural effusion, exacerbation and COPD,
pneumonia or other reasons for respiratory
insufficiency), sternal problems (pain, infection,
re-suturing), medication status
 Neurological status (clinical stroke, convulsions,
subjective cognitive decline)
 Total days of any form of filtration dependency or
haemodialysis dependency
 Survival status obtained from hospital or civil registries
 If the patient is deceased, date of death
One-half and 1 year after randomization:
 Survival status obtained from hospital or civil registries
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Data handling and record keeping
Data will be handled in accordance with Danish Data Pro-
tection legislation. All original records (including consent
forms, CRFs and relevant correspondences) will be ar-
chived at the trial site for 15 years to allow inspection by
Copenhagen University or local authorities. The electronic
database file will be anonymized and delivered to the
Danish Data Archive and maintained for 15 years.
Ethical considerations and approvals
The trial will be conducted in adherence to the current
version of the Helsinki Declaration, the Danish Law on
Protection of Personal Information and the National
Health Law.
The Regional Ethics Committee of the Danish Capital
Region has approved both the pilot study (protocol no.
H-2-2012-025) and the main trial (protocol no. H-3-
2013-110, July 10 2103), and both pilot study and main
trial protocols were also approved by The Danish Data
Protection Agency (Data Protection Act, project file no.:
2007-58-0015, local file no.: 30–0805 (pilot study) and
local file no.: 30–1434 (main trial).
The trial protocol is registered at ClinicalTrials.gov
(NCT02185885).
The Danish Medicines Agency was consulted but found
no indication for evaluation and approval of this trial be-
cause the trial investigates the importance of MAP during
CPB rather than the effect of a medical drug.
Patients will be enrolled only after written informed
consent has been obtained. No bio-bank will be formed
from the blood samples collected in the trial.
Publication
Upon trial completion, the main manuscript with trial
results, whether positive, negative or neutral, will be sub-
mitted to a major clinical journal for peer review and
publication.
The trial steering and management committee will
grant authorship depending on personal input according
to the Vancouver Principles.
Timeline
A PPCI trial timeline description is presented in Fig. 3.
Collaborators
This trial is investigator-initiated as an interdisciplin-
ary collaboration between the involved departments at
Rigshospitalet, University of Copenhagen, Denmark.
Zenodotus ApS (directed and managed by Dan Høfsten,
MD, PhD) has developed the web-based randomization
system.
Finances
The PPCI trial is funded by The Danish Heart Founda-
tion and research funds at Rigshospitalet, University of
Copenhagen, Denmark. The funding sources have no in-
fluence on trial design, trial conduct, data handling and
analysis, or publication.
Perspectives
It is estimated that each year well over 1 million patients
worldwide undergo cardiac surgery with the use of CBP
[4]. Even though the risk of cerebral injury increases with
age, the mean age of our patient population also increases.
Thus, it seems more pertinent than ever to uncover the
optimal CPB strategy aiming to protect cerebral function
in the best possible way. Despite the fact that CPB has been
employed and used as standard clinical management dur-
ing cardiac surgery for more than 50 years, the safety limits
regarding cerebral perfusion pressure have never been
established. The benefits from a higher MAP versus the
potential harmful side-effects from vasopressors should be
clearly demonstrated, before a decision on an optimal
treatment strategy for MAP during CPB is decided.
2012 2013 2014 2015 2016
Pilot study
Sample size
Writing of main study protocol
Development of web-based randomization
system
Regional Ethics Committee (IRB) approval
Case report form and database design
Main studylogisticpreparation
Main study recruitment phase
Internal monitoring of SAE and lactate levels    ●   ●     
Main study follow up phase
MRI analyses
Background and secondary data analyses
Manuscript preparations
Blood sample analysis
Fig. 3 The Perfusion Pressure Cerebral Infarct (PPCI) project timeline chart
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Discussion
The PPCI trial not only investigates DWI-evaluated cere-
bral lesions, but also aims to correlate these findings to
cognitive function, other neurological manifestations, bio-
markers of cerebral injury etc., thereby applying a clinical
and original perspective on the importance of blood pres-
sure during CPB on cerebral function and monitoring in
relation to open heart surgery.
The fact that the primary endpoint is a surrogate out-
come is a limitation of the trial. However, conducting
stroke and/or mortality studies at a convincingly large
scale seems unethical when a more humble, but still
relevantly powered, investigation applying neuroimaging
can be designed to provide equally important perspec-
tives on the much-debated subject of MAP and the risk
of stroke during cardiac surgery with the use of CPB.
Trial status
The first trial patient was randomised 8 July 2014. We
expect to complete patient recruitment in early 2016.
Additional file
Additional file 1: SPIRIT checklist – recommended items to address in a
clinical trial protocol. (DOC 122 kb)
Abbreviations
ANOVA: analysis of variance; CABG: coronary artery bypass grafting;
CBF: cerebral blood flow; CCS: Canadian Cardiovascular Society grading of
angina pectoris; Cho/Cr: total choline/total creatine; CK-MB: creatine kinase
MB isoenzyme; COPD: chronic obstructive pulmonary disease;
CPB: cardiopulmonary bypass; CPP: cerebral perfusion pressure; CRF: case
report form; DWI: diffusion-weighted magnetic resonance imaging;
EDTA: ethylenediaminetetraacetate; eGFR: estimated glomerular filtration rate;
GFAP: glial fibrillary acidic protein; GME: gaseous microemboli; ICU: intensive
care unit; ICU-LOS: intensive care unit—length of stay; ISPOCD: International
Study of Postoperative Cognitive Dysfunction; LLA: lower limit of (cerebral)
autoregulation; MAP: mean arterial pressure; mL: millilitres; MMP-9: matrix
metallopeptidase 9; MMSE: mini-mental state examination; MRI: magnetic
resonance imaging; MRS: magnetic resonance spectroscopy; NAA/Cr:
n-acetylaspartate/total creatine ratio; NIRS: near infrared spectroscopy;
NSE: neuron-specific enolase; NYHA: New York Heart Association functional
classification of heart failure; PEEP: positive-end expiratory pressure;
POCD: postoperative cognitive dysfunction; PPCI: Perfusion Pressure Cerebral
Infarcts trial; rcSO2: regional (cerebral) oxygen saturation; SAE: severe adverse
events; SDF: sidestream dark field imaging; TnT: troponin T; UCH-L1: ubiquitin
carboxyl-terminal esterase L1.
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